Cell Therapeutics Announces Filing of Form 10-K

SEATTLE, Feb. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2009 (the "Annual Report on Form 10-K"). This filing is available for review on CTI's website at www.CellTherapeutics.com, or on the Securities and Exchange Commission's website at www.sec.gov.

As required under NASDAQ Marketplace Rule 5250(b)(2), CTI also announced that its consolidated financial statements for the fiscal year ended December 31, 2009, included in the Annual Report on Form 10-K, contained a "going concern" qualification from its independent registered public accounting firm.  This announcement does not represent any change or amendment to CTI's fiscal year 2009 financial statements or to its Annual Report on Form 10-K.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

SOURCE Cell Therapeutics, Inc.